Search PubMed⌕ Search

Biomedical subjects

C M Smith

Publications and source records attributed to C M Smith.

At least 361 records · Page 20Linked to original sources

A new goldfish model to evaluate pharmacokinetic and pharmacodynamic effects of drugs used for motion sickness in different gravity loads.

This paper proposes a new goldfish model to predict pharmacodynamic/pharmacokinetic effects of drugs used to treat motion sickness administered in differing gravity loads. The assumption of these experiments is that the vestibular system is dominant in producing motion sickness and that the visual system is secondary or of small import in the production of motion sickness. Studies will evaluate the parameter of gravity and the contribution of vision to the role of the neurovestibular system in the initiation of motion sickness with and without pharmacologic agents. Promethazine will be studied first. A comparison of data obtained in different groups of goldfish will be done (normal vs. acutely and chronically bilaterally blinded vs. sham operated). Some fish will be bilaterally blinded 10 months prior to initiation of the experiment (designated the chronically bilaterally blinded group of goldfish) to evaluate the neuroplasticity of the nervous system and the associated return of neurovestibular function. Data will be obtained under differing gravity loads with and without a pharmacological agent for motion sickness. Experiments will differentiate pharmacological effects on vision vs. neurovestibular input to motion sickness. Comparison of data obtained in the normal fish and in acutely and chronically bilaterally blinded fish with those obtained in fish with intact and denervated otoliths will differentiate if the visual or neurovestibular system is dominant in response to altered gravity and/or drugs. Experiments will contribute to validation of the goldfish as a model for humans since plasticity of the central nervous system allows astronauts to adapt to the altered visual stimulus conditions of 0-g. Space motion sickness may occur until such an adaptation is achieved.

Animals↗

Ecgonine methyl ester, a major metabolite of cocaine.

Most assays for the identification of cocaine use are aimed at detection of benzoylecgonine, a major urinary metabolite. Gas chromatography assays require derivatization of benzoylecgonine. Recently, ecgonine methyl ester (methylecgonine) has been shown to be major urinary metabolite of cocaine in man after oral administration. These results indicate that ecgonine methyl ester is a prominent urinary metabolite after street use of cocaine, which primarily involves intranasal application and intravenous injection rather than ingestion. Advantages of GC/MS analysis for ecgonine methyl ester in identifying cocaine use include the ability to chromatograph it on common stationary phases without derivatization and its early elution.

Chromatography, Thin Layer↗

Comparison of quinidine by fluorescence polarization immunoassay and high pressure liquid chromatography.

Analysis of quinidine was performed using fluorescence polarization immunoassay (Abbott TDXTM) with an ion-pairing adsorption high pressure liquid chromatography (HPLC) technique as the comparative method. Correlation of 110 clinical samples was excellent (r2 = 0.983). TDX calibration appeared stable for 14 days. There is minimal contribution to the concentration of quinidine due to the presence of metabolite. The TDX method is rapid, precise, and accurate.

Antibody Specificity↗